Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)

Merck KGaA (EMD Serono) logo

Merck KGaA (EMD Serono)

Status

Completed

Conditions

Multiple Sclerosis

Study type

Observational

Funder types

Industry

Identifiers

NCT01034644
EMR200136_022

Details and patient eligibility

About

This study, PRISMS-15 is a single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial. The aim of this trial is to provide additional data on the driving factors of IFN beta response and the long-term outcomes of Rebif® treatment. This is a Phase IV trial involving subjects who previously participated in the PRISMS trial. To address the trial objectives, a single visit will be performed, at least 3 months after the onset of the last relapse.

Enrollment

290 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Was randomized in the PRISMS study
  • Is willing and able to comply with the protocol
  • Written informed consent given before any trial-related activities are carried out

Exclusion criteria

Is unwilling or unable to participate in the study

Trial design

290 participants in 1 patient group

PRISMS patients
Description:
This single group includes all the patients from the PRISMS study

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems